MedTrace Logo

Pemetrexed in Patients With Soft Tissue Sarcoma

NCT00427466 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2009-02-16

No results posted yet for this study

Summary

The aims of this trial are to evaluate the efficacy and tolerability of pemetrexed in patients with metastatic soft tissue sarcoma who have progressed after or during an anthracycline-based chemotherapy and to assess the toxicity profile

Conditions

  • Sarcoma

Interventions

DRUG

Pemetrexed

Sponsors & Collaborators

  • Arbeitsgemeinschaft fur Internistische Onkologie

    collaborator OTHER

  • German Sarcoma Group

    collaborator OTHER

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Joerg T Hartmann, MD · Medical Center II, University of Tuebingen, Germany

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00427466 on ClinicalTrials.gov